Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II trial of the hellenic cooperative oncology group

Clinical Breast Cancer

Volumn 10, Issue 3, 2010, Pages 230-237

  Gogas, Helen ^a   Pectasides, Dimitrios ^b   Kostopoulos, Ioannis ^c   Lianos, Evangelos ^d   Skarlos, Dimosthenis ^e   Papaxoinis, George ^b   Bobos, Mattheos ^c   Kalofonos, Haralabos P ^f   Petraki, Kalliopi ^e   Pavlakis, Kitty ^g   Bafaloukos, Dimitrios ^e   Fountzilas, George ^c  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d ALEXANDRA HOSPITAL   (Greece)

^e METROPOLITAN HOSPITAL   (Greece)

^f UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^g Department of Pathology   (Greece)

Author keywords

EGFR; ERCC1; FISH; HER2; Ki 67; MAP ; TMA

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; KI 67 ANTIGEN; METHOTREXATE; MICROTUBULE ASSOCIATED PROTEIN; PACLITAXEL; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; LEUKOPENIA; LOCALLY ADVANCED BREAST CANCER; MASTECTOMY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; ONCOGENE; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TISSUE MICROARRAY; TISSUE SECTION; TREATMENT RESPONSE; VOMITING;

EID: 77952990423     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.031     Document Type: Article

References (44)

1. Buzdar AU. Preoperative chemotherapy treatment of breast cancer-a review. Cancer 2007; 110:2394-2407
2. Fountzilas G, Dimopoulos AM, Papadimitriou C, et al. First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 1998; 9:1031-1034
3. Perez EA, Hillman DW, Stella PJ, et al. A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000; 88:124-131
4. Fountzilas G, Kalofonos HP, Dafni U, et al. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004; 15:1517-1526 (Pubitemid 39409743)
5. Fountzilas G, Dafni U, Dimopoulos MA, et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2009; 115:87-99.
6. Fountzilas G, Athanassiadis A, Kalogera-Fountzila A, et al. Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group. Eur J Cancer 1997; 33:1893-1895 (Pubitemid 28129223)
7. Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007; 18:1927-1934.
8. Bhat KM, Setaluri V. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 2007; 13:2849-2854
9. Olaussen KA, Dunant A, Fouret P, et al. IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-991
10. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003; 77:109-114
11. Surveillance, Epidemiology and End Results [Web site]. SEER Program Coding and Staging Manual 2007, Appendix C: p. C-610. Available at: http://www.seer.cancer.gov/tools/codingmanuals. Accessed: March 15, 2010.
12. Jellife RW. Letter: creatinine clearance bedside estimate. Ann Intern Med 1973; 79:604-605
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655
14. Williams JH, Mepham BL, Wright DH. Tissue preparation for immunocytochemistry. J Clin Pathol 1997; 50:422-428
15. Scartozzi M, Bearzi I, Berardi R, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies [published erratum in: J Clin Oncol 2005; 23:248]. J Clin Oncol 2004; 22:4772-4778
16. Rouzier R, Rajan R, Wagner P, et al. Microtubule-associated protein Tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005;102:8315-8320
17. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11:155-168
18. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006; 24:4170-4176
19. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-145
20. Frasci G, D'Aiuto G, Comella P, et al. Southern Italy Cooperative Oncology Group (SICOG): weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs. triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a SICOG phase III study. Br J Cancer 2006; 95:1005-1012
21. Alarcon-Rozas AE, Galvez J, Venegas D, et al. Pathological complete response (pCR) in stage II and III breast cancer patients treated with neoadjuvant chemotherapy (CT): dose-dense ACx4 followed by carboplatin/taxol days 1-8. Paper presented at: the ASCO 2007 Breast Cancer Symposium; September 7-8, 2007; San Francisco, CA. Abstract No: 220.
22. Ezzat AA, Ibrahim EM, Ajarim DS, et al. Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer 2004; 90:968-974
23. Hsu C, Huang CS, Chao TY, et al. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma. Cancer 2002; 95:2044-2050
24. Hurley J, Reis I, Silva O, et al. Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. Clin Breast Cancer 2005; 5:447-454
25. Roy V, Pockaj BA, Northfelt DW, et al. N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer. J Clin Oncol 2008; 26(15 suppl.):21s (abstract 563).
26. Coudert BP, Largillier R, Arnould L, et al. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007; 25:2678-2684
27. Han HS, Doliny P, Blaya M, et al. Dose-dense docetaxel, carboplatinum and trastuzumab (ddTCH) as neoadjuvant therapy for human epidermal receptor 2 (HER2) positive breast cancer. J Clin Oncol 2007; 25(18 suppl):594s (abstract 11003).
28. Dawood S, Ueno NT, Cristofanilli M. The medical treatment of inflammatory breast cancer. Semin Oncol 2008; 35:64-71. (Pubitemid 351282392)
29. Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005; 97:966-975
30. Ardavanis A, Scorilas A, Tryfonopoulos D, et al. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and fluorouracil chemotherapy, surgery, and radiotherapy: long-term results. Oncologist 2006; 11:563-573
31. Walker RA. Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol 2008; 61:689-696
32. Tsutsui S, Kataoka A, Ohno S, et al. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 2002; 8:3454-3460
33. Buchholz TA, Tu X, Ang KK, et al. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer 2005; 104:676-681
34. Somlo G, Chu P, Frankel P, et al. Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome. Ann Oncol 2008; 19:1853-1859
35. Al-Kuraya K, Schraml P, Torhorst J, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004; 64:8534-8540
36. Van Poznak C, Tan L, Panageas KS, et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002; 20:2319-2326
37. Tzaida O, Gogas H, Dafni U, et al. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Oncology 2007; 72:388-396
38. Koutras AK, Kalogeras KT, Dimopoulos MA, et al. Hellenic Cooperative Oncology Group (HeCOG): evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Br J Cancer 2008; 99:1775-1785
39. Andre F, Hatzis C, Anderson K, et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007; 13:2061-2067
40. Pentheroudakis G, Kalogeras KT, Wirtz RM, et al. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat 2009; 116:131-143
41. Rody A, Karn T, Gätje R, et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 2007; 16:86-93.
42. Bernard-Marty C, Treilleux I, Dumontet C, et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer 2002; 3:341-345
43. Galmarini CM, Treilleux I, Cardoso F, et al. Class III {beta}-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 2008; 14:4511-4516
44. Pusztai L, Jeong J, Gong Y, et al. Evaluation of microtubule associated protein tau expression as prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. Paper presented at: the 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 54.